Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation

Olmesartan medoxomil (OLM) is a first-line antihypertensive drug with low oral bioavailability (28.6%). This study aimed to develop oleogel formulations to decrease OLM side effects and boost its therapeutic efficacy and bioavailability. OLM oleogel formulations were composed of Tween 20, Aerosil 20...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Dahmy, Rania Moataz, Elsayed, Ibrahim, Hussein, Jihan, Althubiti, Mohammad, Almaimani, Riyad A., El-Readi, Mahmoud Zaki, Elbaset, Marawan A., Ibrahim, Bassant M. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146305/
https://www.ncbi.nlm.nih.gov/pubmed/37111569
http://dx.doi.org/10.3390/pharmaceutics15041083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146305/
https://www.ncbi.nlm.nih.gov/pubmed/37111569
http://dx.doi.org/10.3390/pharmaceutics15041083

Ejemplares similares